Exelixis, Inc. (EXEL) News
Filter EXEL News Items
EXEL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EXEL News Highlights
- For EXEL, its 30 day story count is now at 6.
- Over the past 14 days, the trend for EXEL's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about EXEL are BEAM, PAY and PHVS.
Latest EXEL News From Around the Web
Below are the latest news stories about EXELIXIS INC that investors may wish to consider to help them evaluate EXEL as an investment opportunity.
11 Stocks Insiders and Billionaires Are Crazy AboutIn this article, we will take a detailed look at the 11 Stocks Insiders and Billionaires Are Crazy About. For a quick overview of such stocks, read our article 5 Stocks Insiders and Billionaires Are Crazy About. In his famous book titled One Up on Wall Street, Peter Lynch talks about how average investors miss out on opportunities by […] |
Is the Options Market Predicting a Spike in Exelixis (EXEL) Stock?Investors need to pay close attention to Exelixis (EXEL) stock based on the movements in the options market lately. |
Why Is Beam Therapeutics Inc. (BEAM) Up 29.5% Since Last Earnings Report?Beam Therapeutics Inc. (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023ALAMEDA, Calif., December 07, 2023--Exelixis, Inc. (Nasdaq: EXEL) today announced that it will webcast the Exelixis 2023 R&D Day: Science & Strategy event taking place on Tuesday, December 12, 2023, from 9:00 a.m. to 12:30 p.m. EST. During the event, featured speakers will review the progress of the company’s growing research and development pipeline, highlight recent clinical updates and elaborate on the company’s continued efforts to serve more patients with cancer and generate sustainable, lo |
Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study DataUpdates from Exelixis (EXEL) and Pharvaris (PHVS) are in the spotlight this week. |
Exelixis (EXEL) Collaborates With Arcus for Kidney Cancer StudyExelixis (EXEL) partners with Arcus Biosciences for a phase Ib/II study to evaluate zanzalintinib in combination with AB521 for ccRCC. |
Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck CancerALAMEDA, Calif., December 04, 2023--Exelixis, Inc. (Nasdaq: EXEL) today announced the initiation of STELLAR-305, a phase 2/3 pivotal trial evaluating zanzalintinib in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1-positive recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). |
Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell CarcinomaALAMEDA, Calif. & HAYWARD, Calif., December 04, 2023--Exelixis, Inc. (Nasdaq: EXEL) and Arcus Biosciences (NYSE: RCUS) today announced that the companies have entered into a clinical trial collaboration for STELLAR-009, a phase 1b/2 trial evaluating zanzalintinib, Exelixis’ next-generation tyrosine kinase inhibitor (TKI), in combination with AB521, an inhibitor of the transcription factor HIF-2⍺, in patients with advanced solid tumors, including clear cell renal cell carcinoma (ccRCC). Exelixis |
Exelixis (EXEL) Up 8.4% Since Last Earnings Report: Can It Continue?Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023ALAMEDA, Calif., November 21, 2023--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28 at 11:00 am ET / 8:00 am PT. |